Purpose: Major depressive disorder (MDD) has detrimental effects on health-related quality of life (HRQoL). We describe the effect of vortioxetine on HRQoL in MDD patients by using patient-reported outcome instruments.
INTRODUCTION
Major depressive disorder (MDD) is a debilitating medical condition that results in burdens on individuals, families, and society and is a significant cause of disability worldwide. MDD is characterized by the presence of Z1 major depressive episode (MDE) with symptoms including depressed mood, loss of interest or pleasure, disturbed sleep, reduced appetite, low energy, feelings of guilt and/or low self-worth, and poor concentration. These problems can lead to substantial impairments in health-related quality of life (HRQoL) as well as in the ability to take care of everyday responsibilities.
Depression recurs in up to 80% of all patients with MDD who have achieved remission; it can become chronic (ie, lasting Z2 years) in nearly 20% of patients.
1,2 The risk of relapse or recurrence, chronicity (as measured by the duration of episodes), and treatment resistance increases with each new MDE. Thus, treatment to full remission (often defined as a score r7 on the 17-item Hamilton Depression Scale or a 50%-80% reduction on this scale compared with the beginning of treatment) and continued treatment to prevent relapse or recurrence have high priority in the management of MDD. 3, 4 Furthermore, depression may lead to suicide; the mortality rate due to suicide is 10% to 15% among patients with MDD treated by psychiatrists. [5] [6] [7] It is widely recognized that the mood symptoms of MDD are associated with impairment in perceived health; reductions in a patient's physical, psychological, and social functioning; and a range of HRQoL domains related to overall well-being. [8] [9] [10] [11] [12] [13] [14] Although a variety of antidepressants are available, only about one third of acutely treated patients achieve remission. 15 Moreover, even after undergoing multiple antidepressant therapies, 430% of patients remain symptomatic in the short term: 2 of 5 patients with clinical depression do not respond adequately to antidepressant treatment even after they have completed fourth-line therapy. 16 A recent study of remitted MDD patients suggests that physical and mental functioning remained lower in remitted patients compared with the general population, highlighting that antidepressant therapies do not always prevent residual symptoms. 17 The results of the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study suggest that greater depressive symptom severity is directly associated with poorer HRQoL, with significant impairments seen across psychological, physical, and social domains. 10, 18 Therefore, the assessment of HRQoL, as part of the ongoing evaluation of depression treatment, is necessary for clinicians and patients. 14 The assessment of HRQoL depends largely on the selection of the appropriate HRQoL tools. 19 Studies have demonstrated the relevance of traditional subjective assessment scales such as the 36-item Short-Form Health Survey (SF-36), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), the EuroQol 5-Dimension Questionnaire (EQ-5D), and the Health Status Questionnaire-12 (HSQ-12) 10, 18, 20, 21 for the assessment of HRQoL in patients with MDD. The rest of the listed scales are generic but contain different domains capturing various aspects of the patient's functioning and HRQoL, as well as overall perceptions of quality of life ( Table I) . The utilization of the range of different HRQoL measures enables a comprehensive evaluation of aspects of HRQoL and functioning relevant to patients with depression. 22 Vortioxetine (Lu AA21004) is an antidepressant with a multimodal mechanism of action 23 approved in Europe for the treatment of MDEs in adults and in the United States for the treatment of adults with MDD. The clinical development program for vortioxetine that supported the marketing authorization application for MDD or MDE in Europe entailed 13 short-term studies, 3 long-term extension studies, and 1 twelve-month relapse-prevention study; these studies included nearly 6000 patients with a total exposure of 42000 patient-years. As of January 2015, the total clinical development program for vortioxetine in these indications entailed 17 shortterm studies, 5 long-term extension studies, and 1 twelve-month relapse-prevention study; this program included 49700 patients with a total exposure of 43450 patient-years.
The aim of the present analysis was to report the effect of vortioxetine on HRQoL in adult patients with MDD in randomized placebo-controlled studies, as evaluated by using various HRQoL instruments.
MATERIALS AND METHODS Vortioxetine Registration Studies
The present across-study comparison of HRQoL included the 5 short-term (6-8 weeks) studies conducted in adults aged 18 to 75 years (NCT00672958, NCT00735709, NCT00635219, NCT00839423, and NCT01140906), and 1 dedicated study in elderly patients aged Z65 years (NCT00811252) in which quality of life measures were included for evaluation. [24] [25] [26] [27] [28] [29] The primary efficacy end point in the shortterm trials was the change from baseline to week 6/8 on the Montgomery-Åsberg Depression Rating Scale or the 24-item Hamilton Depression Scale total score to evaluate the effect of vortioxetine on depressive symptoms. The primary statistical method applied used either a mixed model for repeated measures (MMRM) analysis using all available observed data or an analysis of covariance (ANCOVA) model using the last-observation-carried-forward (LOCF).
Only patients who received the approved doses of 
HRQoL Assessment Measures
The vortioxetine clinical development program also used various patient-reported outcome measures and functioning instruments (Table II) to assess overall HRQoL after consultation with experts in the field of health-related outcomes. The program included the following validated measures: the SF-36 version 2 30, 31 ; the Q-LES-Q-Short Form (Q-LES-Q-SF) 32, 33 ; the EQ-5D 34 ; and the HSQ-12 (version 2.0). 35 All of the instruments meet established criteria for the measurement of HRQoL and overall functioning, and they have been psychometrically validated in MDD or related disorders. The measures were also appropriately linguistically adapted and validated to ensure cross-cultural relevance across the broad range of countries included within the trials. Finally, the instruments are clinically well established, widely used in many disease areas, highly relevant to a depressed population, and capture information that can provide substantial value to physicians making treatment decisions 22, 36 (Appendices I and II).
36-Item Short-Form Health Survey
The SF-36 version 2 is designed to measure generic HRQoL concepts relevant across age, disease, and treatment groups and has been widely used and validated in patients with MDD [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] and other mental health disorders. [47] [48] [49] [50] [51] The questionnaire consists of 36 questions, which yield a profile of 8 domains: physical functioning, bodily pain, role physical (limitations in usual role activities due to physical problems), role emotional (limitations in usual role activities due to emotional problems), general health, vitality, social functioning, and mental health. These domains are used to derive 2 broader measures: the mental component summary (MCS) and the physical component summary (PCS). 30, 31 In the PCS, mental dimensions (including mental health, social functioning, and role emotional) have negative weights, whereas physical domains (eg, physical functioning, role physical, bodily pain, general health) are assigned positive weights of higher values, and energy/vitality and social functioning are neutrally weighted. Very low PCS scores indicate severe physical dysfunction, severe social and role disability, distressful bodily pain, frequent tiredness, and unfavorable evaluation of health status. For the MCS, positive weights are placed on the mental health, role emotional, social function, and vitality scales, whereas substantial negative weights are placed on the physical function and role physical scales. Very low scores on the MCS indicate frequent psychological distress and severe social and role disability due to emotional problems. In the treatment of a mental illness, no detectable effect is expected on the physical dimensions of the SF-36 because patients generally do not report impairment on these dimensions (which tend to be at the level of the norm in general population at baseline). This is in contrast to the MCS, in which patients with mental health disorders have scored significantly lower than the norms of the general population.
31,52

Quality of Life Enjoyment and Satisfaction Questionnaire
The Q-LES-Q 32 is a patient-reported outcome instrument designed to measure enjoyment and satisfaction in various areas of daily life. The short-form version (Q-LES-Q-SF) 53 was designed for and validated in subjects with a wide range of medical and psychiatric disorders and has recently been used extensively in depressed populations. 38, [54] [55] [56] [57] [58] [59] The various areas of daily functioning assessed by using the Q-LES-Q-SF 32 include those that may be affected by depression, suggesting its relevance and content validity. The Q-LES-Q-SF contains 16 items that assess satisfaction or enjoyment related to physical health, medications, feelings, work/school, household duties, leisure-time activities, social relations, and general activities. The Q-LES-Q was piloted with 95 outpatients experiencing depression to validate the 8 summary scales derived from 93 items reflecting the major domains.
EuroQol 5-Dimension Questionnaire
The EQ-5D is a standard generic measure of HRQoL, used mainly to assess the value of health interventions in cost-utility studies. 60 It is often used to complement other quality of life measures and has been applied in numerous studies of depression. 38, 61, 62 The EQ-5D consists of 2 sections (the EQ-5D descriptive system and the EQ visual analog scale [VAS] ) and has been validated in populations with depression. 63, 64 The EQ-5D descriptive system includes the 5 domains of mobility, self-care, usual activities, pain/ discomfort, and depression/anxiety, which are rated I. Florea et al.
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by patients using a 3-point Likert scale (1 = no problems; 2 = some problems; 3 = extreme problems). The EQ-5D VAS measures the patient's perception of his or her health state on a vertical graduated VAS that ranges from 0 to 100 (worst to best imaginable health state). The results of the EQ-5D VAS are the focus of the analyses presented in this article. 34 
12-Item Health Status Questionnaire
The HSQ-12 is a generic, patient-reported outcome instrument designed to evaluate physical, emotional, and social functioning, with a focus on the elderly. The HSQ-12 was developed from the original 39-item HSQ, from which the SF-36 was also derived; it thus demonstrates content validity similar to the SF-36. As with the SF-36, items in the HSQ-12 cover important aspects of health that are known to be adversely affected by mood disorders (including MDD) 65 and advanced age. 66 The HSQ-12 displays high predictive validity for patients with depression. The HSQ-12 includes 12 items that use Likert-type single-stimulus responses, consisting of between 3 and 6 possible options. To score the HSQ-12, responses are transformed to a scale of 0 to 100, and 8 scales are calculated from the 12 items (thus maintaining the 8-domain structure of the SF-36). Six of the 8 scales contain single items, with 2 scales (physical functioning and mental health) each containing 3 items averaged together. A higher score indicates better health. 35 
Statistical Methods
A random effects meta-analysis 67 was performed on the results from the short-term vortioxetine studies by using both MMRM and ANCOVA, LOCF (as a sensitivity analysis) for individual studies based on the full analysis set (FAS) at the end of study period. For the HRQoL variables used only in individual studies, an MMRM analysis was conducted, with the exception of the Q-LES-Q-SF, for which ANCOVA, LOCF was conducted because this instrument was only administered once after baseline and at the last visit (upon completion or withdrawal). MMRM was chosen as the primary analysis based on the advantages related to estimation bias, 68 with MMRM models run on observed cases with freely varying mean and covariance structures; treatment and center were used as fixed factors and baseline score as a covariate interacting with visit. The ANCOVA, LOCF analysis was used as a sensitivity analysis with no direct or indirect comparison of the 2 analysis methods. The standardized mean differences to placebo interpreted as Cohen's d standardized effect size (SES) were used (using the standard 0.2 threshold for clinical relevance, based on the research of Leucht et al 69 )
. This method allows a comparison of the magnitude of the effect sizes between studies and the different assessment tools. All analyses were performed by using SAS version 9.1 (SAS Institute, Inc, Cary, North Carolina).
RESULTS
Patient Population
The populations in the 6 short-term MDD studies in adults were similar with regard to disease characteristics and demographic characteristics, with a few exceptions. The mean age of the patients ranged between 42 and 47 years in the individual studies (overall individual study range, 18-75 years), and 66% of participants were women (overall individual study proportion of women, 60.3%-76.0%). Mean age in the dedicated elderly study was 71 years, and 66% of patients were women. In the 5 short-term studies in nonelderly adults, most patients were white (81%), 13% were black, and 6% were Asian. There were some differences in racial composition across the studies because they were conducted in different geographical regions.
36-Item Short-Form Health Survey
Assessment of SF-36 in the vortioxetine clinical trial program was calculated by using the 2 broader components of health: the MCS and the PCS. 30, 31 The impact of vortioxetine on more specific HRQoL domains from the SF-36 was also assessed to present a more complete picture of MDD-related outcomes.
SF-36 MCS Score
The SF-36 MCS was calculated for 4 short-term studies conducted in adults and reported as change from baseline versus placebo at study end point (week 6/8). The 5-mg dose of vortioxetine was included in all 4 studies and separated from placebo (P o 0.05) in 2 of them, with the mean difference from placebo ranging between 3.4 and 4.8 points. Vortioxetine 10 mg was also included in the 3 studies and separated from placebo (P o 0.05) in each, with a mean difference from placebo of 4.0 and 6.2 points.
In the meta-analysis of the mean change from baseline in SF-36 MCS score (FAS, MMRM) at week 6/8, the overall mean difference of vortioxetine from placebo was statistically significant: 2.6 points (P = 0.001) in favor of vortioxetine 5 mg, and 4.8 points (P o 0.001) in favor of vortioxetine 10 mg (Figure 1) . The clinical relevance of the results was supported by the SES, which exceeded the standard 0.2 threshold (vortioxetine 5 mg, SES of 0.22 [range in the individual studies (Table II) Table III) .
The ANCOVA, LOCF analyses of the individual studies produced results similar to those in the MMRM analyses, with the exception that the 5-and 10-mg doses did not separate from placebo in study NCT00839423. The ANCOVA, LOCF meta-analysis yielded results similar to the MMRM meta-analysis.
SF-36 PCS Score
The MMRM meta-analysis of the mean change from baseline in the SF-36 PCS score at week 6/8 exhibited numerically greater changes for vortioxetine but not a statistically significant separation from placebo in the individual studies nor in the metaanalysis of the 4 short-term studies (vortioxetine 5 mg, change of 0.49, P ¼ 0.192, SES of 0.08, n ¼ 0.06; vortioxetine 10 mg, change of 0.52, P ¼ 0.282, SES of 0.08, n ¼ 0.08; FAS, MMRM). The meta-analysis of SF-36 PCS results were analyzed by using ANCOVA, LOCF and yielded similar results. 
Clinical Therapeutics 2316
Volume 37 Number 10
SF-36 Domain Scores
The meta-analysis of the mean changes from baseline in SF-36 domain scores at week 6/8 (FAS, MMRM) demonstrated a significant improvement for vortioxetine 5 mg (P o 0.05) versus placebo in increasing the role physical, vitality, social functioning, role emotional, and mental health scores (Figure 2 
Q-LES-Q-SF Scores
HSQ-12 Scores
The HSQ-12 was included in the dedicated elderly study (NCT00811252) to assist in understanding the functional benefits of vortioxetine in elderly patients with MDD. In the MMRM analyses of the mean change from baseline in HSQ-12 domain scores at week 8, vortioxetine 5 mg demonstrated a statistically significant separation from placebo on the domains of health perception (change of 10. 
DISCUSSION
Depressive disorders were identified as a leading cause of disease burden in the 1990 and 2000 Global Burden of Disease studies, 70, 71 with depressive disorders ranked as the fourth leading cause of burden in 2000 (equivalent to 4.4% of all disability-adjusted life-years), after perinatal conditions, lower respiratory tract infections, and HIV/AIDS. 71 MDD was also identified as the leading cause of disability, responsible for 13.4% of the years of life lived with a disability in women and 8.3% in men. The Medical Outcomes Survey found that compared with a normalized population, patients with MDD demonstrate significant impairments in HRQoL, including reductions in daily life; physical, psychological, and social functioning; and overall well-being. 9, 10, 14, 17 To comprehensively evaluate HRQoL benefits in patients with MDD, the assessment of at least 3 specific domains of health (physical, psychological, and social) has been recommended, using various subjective and objective assessments such as symptoms, ability to function, and overall disability. 32 HRQoL instruments were incorporated into the vortioxetine clinical development program to evaluate the treatment effect on patients' physical, emotional, and social health, and on general daily life. 31 A recent, secondary, post hoc analysis of a doubleblind, placebo-controlled trial of desvenlafaxine in patients with MDD evaluated the relationship of depressive symptoms and functional outcomes. 97 Desvenlafaxinetreated patients in the modified intention-to-treat sample exhibited significantly greater improvement in several functional outcomes in the responder, nonanxious, and normal-energy patient subgroups. Functional improvement after 12 weeks of desvenlafaxine treatment was greater in these patient subgroups and was predicted by an early improvement in depressive symptoms in employed MDD patients. In a randomized study of venlafaxine ER in adult outpatients with recurrent MDD, better overall psychosocial functioning was observed among patients randomly assigned to receive venlafaxine ER (n ¼ 129) versus placebo (n ¼ 129), with significant differences at end point on SF-36 role function-emotional, the Q-LES-Q, and the Social Adjustment ScaleSelf-Report total, and work, house work, social/ leisure, and extended-family factor scores (P r 0.05). After 2 years of treatment, significant differences favored venlafaxine ER (n ¼ 43) versus placebo (n ¼ 40) on SF-36 vitality and role function-emotional, the Q-LES-Q Life Enjoyment Scale-Short Version, and Social Adjustment Scale-Self-Report total, social/leisure, and extended-family factor scores (P r 0.05). 42 Although these studies suggest the clinical benefits of available antidepressant therapies on HRQoL, there is limited assessment of any available antidepressant therapy beyond the SF-36.
The present analysis of HRQoL was performed on the short-term, placebo-controlled pivotal registration studies of vortioxetine in adults with MDD. The results of the individual clinical studies are supportive of vortioxetine's efficacy profile in depressive symptoms and demonstrated a statistically significant difference from placebo in favor of vortioxetine treatment for patients with MDD. In terms of specific quality of life improvements, vortioxetine separated from placebo (P o 0.05) at week 6/8 on SF-36 MCS score (evaluated at 5 and 10 mg/d). The effect on SF-36 MCS was clinically relevant, as supported by the SES, which exceeded the Cohen's d threshold of 0.2. In depression, reaching a meaningful separation from placebo is rare, and although the results suggest the minimal important difference, when looking at the changes over time, significant and meaningful improvements within a group can also be noted. The meta-analysis of all the short-term studies in adults support the results of the individual studies and showed a statistically significant difference from placebo in favor of vortioxetine and an increased effect with increasing dose. The favorable effect of vortioxetine (at 5 and 10 mg/d) was corroborated by the associated statistically significant increases in all 4 of the SF-36 domain scores (vitality, social functioning, role emotional, and mental health) that are most relevant to mental health conditions. The SF-36 PCS score is a component score based on physical well-being. The patients included in the short-term vortioxetine studies in adults with MDD were generally in good physical health (as prespecified on the clinical trial inclusion criteria), and therefore no or limited improvement in the score was expected or reported. The improvement in HRQoL observed with the SF-36 MCS score is supported by the separation from placebo (P o 0.05) at week 6/8 in favor of vortioxetine in the EQ-5D score and Q-LES-Q total and life-satisfaction scores. The effect on the Q-LES-Q and EQ-5D in NCT01140906 and NCT00839423, respectively, were supported by the SES for vortioxetine 10, 15, and 20 mg/d.
These improvements in HRQoL were replicated in the dedicated elderly study, in which vortioxetine 5 mg/d separated from placebo (P o 0.05) on the HSQ-12 subscale scores for health perception, mental health, and energy at week 8. The overall improvements in HRQoL in the elderly populations were similar to those seen in the overall adult MDD population and are of particular importance given the prevalence and burden of depressive symptoms in this specific patient group.
This evaluation of HRQoL in the vortioxetine clinical trial program does have certain limitations. Not all instruments were used in all clinical trials, with 3 of the 4 assessment tools only used in 1 study each. Furthermore, the trial designs include doses ranging from 1 to 20 mg, with only 1 trial that assessed quality of life using the 15-and 20-mg doses. In addition, the SF-36 was not evaluated in the higher dose study, and the overall negative clinical efficacy results of the NCT00672958 trial also directly reflect a lack of effect on the SF-36 MCS in that trial; this potentially confounds the perceived treatment benefit of vortioxetine on the SF-36 MCS. The patient populations in the clinical trials were prespecified to be of good overall general health, limiting any potential results on physical symptoms of the SF-36 PCS, as well as any potential subgroup findings of the Q-LES-Q and HSQ-12, which contain physical components. These limitations affect the potential generalizability of these findings beyond the clinical trial setting and suggest the need for future studies to evaluate the effect of vortioxetine on overall physical functioning.
CONCLUSIONS
MDD is a disabling and chronic disease that diminishes well-being, functioning, and quality of life. HRQoL is recognized as an important outcome measure in the management of patients with MDD, with several multidimensional assessment scales (including the SF-36, EQ-5D, HSQ-12, and Q-LES-Q-SF) validated for use in a population with depression.
Treatment with vortioxetine, which is effective in the short-term treatment of patients with MDD, was associated with significant, clinically meaningful improvements in HRQoL, including specific improvements on the SF-36 mental health domains of vitality, social functioning, role emotional, and mental health, which may translate into meaningful clinical benefits.
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